Results 141 to 150 of about 26,689 (268)

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres

Medical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu   +15 more
wiley   +1 more source

Nucleolin Alterations and ROS Production Associate With Sensitivity of AML Cells to Venetoclax

The FASEB Journal, Volume 40, Issue 19, 15 October 2026.
Venetoclax‐induced Bcl‐2 inhibition corresponds with Mcl‐1 attenuation and decrease of Nucleolin (NCL) level and activity in sensitive cells. Simultaneously, distinct cell subpopulations with opposite mitochondrial (CellROX label, magenta) and cellular (H2DCFDA stain, green) ROS occur, and the H2DCFDA‐positive population shows markers of early ...
Kateřina Wolfová, Petra Otevřelová, Barbora Brodská   +2 more
wiley   +1 more source

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Safety and Feasibility of Magnetic Separation‐Based Blood Purification

Advanced NanoBiomed Research, Volume 6, Issue 10, October 2026.
We present the preclinical biological safety and translational feasibility of a magnetic nanoparticle‐based extracorporeal blood purification platform for removal of disease‐causing blood factors. ISO 10993‐compliant studies and exaggerated worst‐case exposure models demonstrate efficient nanoparticle extraction (≥99.9%), favorable biocompatibility ...
Carlos A. Mora, Laurine Rijsbergen, Jan Waskowski, Gaelle Clermont, Florian Dingreville, Chandrashekara Vishwanath, Rajesh Karunanithi, Alexander Gogos, Jean‐Claude Metzger, Manuel Baumgartner, Joerg C. Schefold, Inge K. Herrmann   +11 more
wiley   +1 more source

Long Term Follow Up of Hereditary Thrombotic Thrombocytopenic Purpura on Plasma Therapy for 9 Years: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT A 7.6‐year‐old boy with hTTP had fever‐induced hemorrhagic rash, MAHA, cerebral infarction, and renal impairment. After plasma therapy, symptoms were partially relieved; 9‐year follow‐up showed regular plasma transfusion was needed, with CKD Stage 3.
Dai Xiaomei, Chen Ruyue, Wu Shuang, Tang Hanyun, Lin Qiang, Li Xiaozhong   +5 more
wiley   +1 more source

Early Integration of CAR T‐Cell Therapy in Mantle Cell Lymphoma: Expert Opinion in the Era of BTK Inhibitors

Hematological Oncology, Volume 44, Issue 6, November 2026.
Carlo Visco, Stefania Bramanti, Paolo Corradini, Enrico Derenzini, Pier Luigi Zinzani   +4 more
wiley   +1 more source

Process Characterization and Determinants of CD3⁺ Cell Yield During Autologous Leukapheresis for CAR-T Cell Manufacturing: A Single-Centre Experience from Western India. [PDF]

Hematol Transfus Cell Ther
Desai P, Navkudkar A, Suresh A, Sengar M, Jain H, Bagal B, Nayak L, Shetty A, Purwar R, Karulkar A, Kalra D, Ravikumar S, Tembhare P.   +12 more
europepmc   +1 more source

Platelet Donation by Apheresis for Female Blood Donors with Low Hemoglobin or Iron Deficiency. [PDF]

Transfus Med Hemother
Infanti L, Pehlic V, Volken T, Stehle G, Holbro A, Buser A.   +5 more
europepmc   +1 more source

Centrifugal Plasma Exchange Versus Double‐Filtration Plasmapheresis in Chronic CIDP: A Randomized Crossover Study Comparing Clinical Outcomes, Biological Effects, Procedure Times, and Costs—The Lymphoapheresis Study

Journal of Clinical Apheresis, Volume 41, Issue 5, October 2026.
ABSTRACT Direct comparisons between centrifugal therapeutic plasma exchange (cTPE) and double‐filtration plasmapheresis (DFPP) remain scarce. We compared cTPE and DFPP in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), regarding clinical outcomes, biological effects, tolerability, session times and hospital costs ...
O. Moranne, S. Chkair, P. Ahmadapoor, C. Prelipcean, T. Chevallier, Ioana Ion, Z. Messikh   +6 more
wiley   +1 more source

Therapeutic Plasma Exchange in Pediatric Patients: A Multi‐Institutional Landscape Analysis

Journal of Clinical Apheresis, Volume 41, Issue 5, October 2026.
ABSTRACT Pediatric evidence for therapeutic plasma exchange (TPE) is largely small, single‐center cohorts; there is no prior large‐scale age‐stratified outcomes assessment. Using the TriNetX US Collaborative Network, we identified 3744 patients ≤ 17 years old undergoing an index TPE procedure, stratified into four age groups (≤ 1, 2–5, 6–12, and 13–17 ...
Caitlin Raymond
wiley   +1 more source